Moreover, SPP1 has been implicated in the upregulation of haptoglobin expression via the PI3K/AKT pathway, with PI3K inhibition reducing SPP1-induced haptoglobin production, positioning it as a potential therapeutic target for acute exacerbations of COPD [89]. Here, HP is linked to chronic obstructive pulmonary disease.